A review of sodium oxybate and baclofen in the treatment of sleep disorders
- PMID: 21476957
- DOI: 10.2174/138161211796197098
A review of sodium oxybate and baclofen in the treatment of sleep disorders
Abstract
Studies examining GABA(B) receptor agonists have reported effects on sleep including decreased sleep onset latency (SOL), increased sleep consolidation and increases in slow wave sleep (SWS). γ-hydroxybutyrate (GHB) is proposed to act as a GABA(B) receptor agonist; however, the mechanism of action of GHB is controversial. In addition, the GABA(B) receptor agonist, baclofen, has also been proposed to exert similar effects on sleep. The aim of this paper is to provide a review of the human clinical studies of sodium oxybate and baclofen regarding sleep and the treatment of sleep disorders including narcolepsy and insomnia, as well as other disorders involving disrupted sleep such as fibromyalgia.
Similar articles
-
Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate.Pediatr Neurol. 2009 Jul;41(1):9-16. doi: 10.1016/j.pediatrneurol.2009.02.008. Pediatr Neurol. 2009. PMID: 19520267 Clinical Trial.
-
Cataleptic effects of gamma-hydroxybutyrate (GHB), its precursor gamma-butyrolactone (GBL), and GABAB receptor agonists in mice: differential antagonism by the GABAB receptor antagonist CGP35348.Psychopharmacology (Berl). 2007 Jun;192(3):407-14. doi: 10.1007/s00213-007-0718-y. Epub 2007 Feb 3. Psychopharmacology (Berl). 2007. PMID: 17277933
-
Differential effects of sodium oxybate and baclofen on EEG, sleep, neurobehavioral performance, and memory.Sleep. 2012 Aug 1;35(8):1071-83. doi: 10.5665/sleep.1992. Sleep. 2012. PMID: 22851803 Free PMC article. Clinical Trial.
-
Behavioral analyses of GHB: receptor mechanisms.Pharmacol Ther. 2009 Jan;121(1):100-14. doi: 10.1016/j.pharmthera.2008.10.003. Epub 2008 Oct 29. Pharmacol Ther. 2009. PMID: 19010351 Free PMC article. Review.
-
gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness.CNS Drugs. 2006;20(12):993-1018. doi: 10.2165/00023210-200620120-00004. CNS Drugs. 2006. PMID: 17140279 Review.
Cited by
-
GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy.J Neurosci. 2014 May 7;34(19):6485-94. doi: 10.1523/JNEUROSCI.0080-14.2014. J Neurosci. 2014. PMID: 24806675 Free PMC article.
-
Challenges in the development of therapeutics for narcolepsy.Prog Neurobiol. 2017 May;152:89-113. doi: 10.1016/j.pneurobio.2015.12.002. Epub 2015 Dec 23. Prog Neurobiol. 2017. PMID: 26721620 Free PMC article. Review.
-
Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review.Curr Pain Headache Rep. 2024 Dec;28(12):1349-1363. doi: 10.1007/s11916-024-01277-9. Epub 2024 Jul 23. Curr Pain Headache Rep. 2024. PMID: 39042299 Free PMC article. Review.
-
Direct activation of G-protein-gated inward rectifying K+ channels promotes nonrapid eye movement sleep.Sleep. 2019 Mar 1;42(3):zsy244. doi: 10.1093/sleep/zsy244. Sleep. 2019. PMID: 30535004 Free PMC article.
-
Hypocretin/Orexin Interactions with Norepinephrine Contribute to the Opiate Withdrawal Syndrome.J Neurosci. 2022 Jan 12;42(2):255-263. doi: 10.1523/JNEUROSCI.1557-21.2021. Epub 2021 Dec 1. J Neurosci. 2022. PMID: 34853083 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical